FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2402177453> ?p ?o ?g. }

• W2402177453 abstract "The majority of melanoma patients treated with a BRAF inhibitor (BRAFi) eventually acquire drug resistance. A major mechanism for acquired resistance is the activation of specific receptor tyrosine kinases (RTKs). We have recently shown that inherent and early adaptive resistance is associated with activation of the JNK-JUN pathway, decreased levels of the SPROUTY negative regulators and a mesenchymal-like phenotype. RTKs have been reported to be regulated by SPROUTY proteins and are able to mediate cell migration and invasion. In this study, we compared the expression and activation of specific RTKs previously linked to BRAFi resistance, within the same cellular background. EGFR, FGFR1, MET and IGF1R were constitutively expressed in the BRAFi-sensitive melanoma cell line A375. The impact of ligand activation of each of these receptors in the presence of BRAFi on proliferation, survival, signalling, morphology, expression of phenotype markers and cell migration was assessed. We also over-expressed SPROUTY2 using an inducible system, to study its role in regulating RTK-mediated BRAFi resistance. In A375 cells, overexpression and activation of either EGFR, FGFR1 or MET were able to reverse inhibition of cell proliferation induced by BRAFi, whereas IGF1R expression and activation was able to reduce cell death induced by high doses of BRAFi, but was unable to reverse inhibition of cell proliferation. The RTKs differed in their ability to activate signalling following treatment with BRAFi. In A375 cells, EGFR, FGFR1 and MET activated by their respective ligands, predominantly induced ERK signalling, whereas ligand activated IGF1R predominantly induced AKT signalling. EGFR activation conferred resistance to BRAFi by overcoming RAF-MEK-ERK pathway inhibition. Activation of EGFR was also able to prevent the early drug adaptive phenotype and reverse the BRAFi-induced changes in the expression of c-JUN, SNAI2, MITF and ZEB2, In contrast activation of IGF1R did not reverse the early drug adaptive phenotype induced by BRAFi. Combination treatment with either an IGF1R or AKT inhibitor was sufficient to overcome IGF1R-mediated survival. Enforced expression of SPROUTY2 reversed the resistance mediated by EGFR or FGFR1 activation. SPROUTY2 expression also conferred sensitivity to BRAFi in LOX-IMV1 cells that were inherently resistant to BRAFi and expressed activated EGFR and FGFR1. Together, our data suggests that RTKs vary in the signalling pathways that are induced upon ligand-activation, particularly in the context of BRAFi resistance. Our findings have clinical relevance for the rational design of drug combinations to target specific RTK signalling and overcome RTK-mediated resistance. Citation Format: Frederic Zhentao Li, Rachel Ramsdale, Amardeep Dhillon, Grant McArthur, Petranel Ferrao. Differences in signalling and phenotypic effects in melanoma between receptor tyrosine kinases that confer resistance to BRAF inhibitors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C70." @default.
• W2402177453 created "2016-06-24" @default.
• W2402177453 creator A5009785835 @default.
• W2402177453 creator A5032415677 @default.
• W2402177453 creator A5048111860 @default.
• W2402177453 creator A5053411708 @default.
• W2402177453 creator A5061399576 @default.
• W2402177453 date "2015-12-01" @default.
• W2402177453 modified "2023-09-27" @default.
• W2402177453 title "Abstract C70: Differences in signalling and phenotypic effects in melanoma between receptor tyrosine kinases that confer resistance to BRAF inhibitors" @default.
• W2402177453 doi "https://doi.org/10.1158/1535-7163.targ-15-c70" @default.
• W2402177453 hasPublicationYear "2015" @default.
• W2402177453 type Work @default.
• W2402177453 sameAs 2402177453 @default.
• W2402177453 citedByCount "0" @default.
• W2402177453 crossrefType "proceedings-article" @default.
• W2402177453 hasAuthorship W2402177453A5009785835 @default.
• W2402177453 hasAuthorship W2402177453A5032415677 @default.
• W2402177453 hasAuthorship W2402177453A5048111860 @default.
• W2402177453 hasAuthorship W2402177453A5053411708 @default.
• W2402177453 hasAuthorship W2402177453A5061399576 @default.
• W2402177453 hasConcept C101544691 @default.
• W2402177453 hasConcept C144174609 @default.
• W2402177453 hasConcept C170493617 @default.
• W2402177453 hasConcept C2775960820 @default.
• W2402177453 hasConcept C42362537 @default.
• W2402177453 hasConcept C502942594 @default.
• W2402177453 hasConcept C55493867 @default.
• W2402177453 hasConcept C57074206 @default.
• W2402177453 hasConcept C62112901 @default.
• W2402177453 hasConcept C62478195 @default.
• W2402177453 hasConcept C75217442 @default.
• W2402177453 hasConcept C86554907 @default.
• W2402177453 hasConcept C86803240 @default.
• W2402177453 hasConcept C95444343 @default.
• W2402177453 hasConceptScore W2402177453C101544691 @default.
• W2402177453 hasConceptScore W2402177453C144174609 @default.
• W2402177453 hasConceptScore W2402177453C170493617 @default.
• W2402177453 hasConceptScore W2402177453C2775960820 @default.
• W2402177453 hasConceptScore W2402177453C42362537 @default.
• W2402177453 hasConceptScore W2402177453C502942594 @default.
• W2402177453 hasConceptScore W2402177453C55493867 @default.
• W2402177453 hasConceptScore W2402177453C57074206 @default.
• W2402177453 hasConceptScore W2402177453C62112901 @default.
• W2402177453 hasConceptScore W2402177453C62478195 @default.
• W2402177453 hasConceptScore W2402177453C75217442 @default.
• W2402177453 hasConceptScore W2402177453C86554907 @default.
• W2402177453 hasConceptScore W2402177453C86803240 @default.
• W2402177453 hasConceptScore W2402177453C95444343 @default.
• W2402177453 hasLocation W24021774531 @default.
• W2402177453 hasOpenAccess W2402177453 @default.
• W2402177453 hasPrimaryLocation W24021774531 @default.
• W2402177453 hasRelatedWork W1936571436 @default.
• W2402177453 hasRelatedWork W1968999855 @default.
• W2402177453 hasRelatedWork W1970323663 @default.
• W2402177453 hasRelatedWork W2000876153 @default.
• W2402177453 hasRelatedWork W2096027620 @default.
• W2402177453 hasRelatedWork W2177766892 @default.
• W2402177453 hasRelatedWork W2182017987 @default.
• W2402177453 hasRelatedWork W2238345281 @default.
• W2402177453 hasRelatedWork W2333820433 @default.
• W2402177453 hasRelatedWork W2340213079 @default.
• W2402177453 hasRelatedWork W2344214299 @default.
• W2402177453 hasRelatedWork W2400597624 @default.
• W2402177453 hasRelatedWork W2557013911 @default.
• W2402177453 hasRelatedWork W2594062880 @default.
• W2402177453 hasRelatedWork W2615601352 @default.
• W2402177453 hasRelatedWork W2626445265 @default.
• W2402177453 hasRelatedWork W2887078648 @default.
• W2402177453 hasRelatedWork W2988280472 @default.
• W2402177453 hasRelatedWork W3012023838 @default.
• W2402177453 hasRelatedWork W3037036795 @default.
• W2402177453 isParatext "false" @default.
• W2402177453 isRetracted "false" @default.
• W2402177453 magId "2402177453" @default.
• W2402177453 workType "article" @default.